Our company (trading as PocDoc) is the market leader in using smartphone technology to massively increase early detection of the biggest preventable diseases affecting the UK and global healthcare systems. The diseases are Cardio, Metabolic and Renal diseases -- heart attacks, strokes, type 2 diabetes and chronic kidney disease (CKD). Together, these three conditions suck up 25% of all NHS spend and are up to 80% preventable. Our technology helps healthcare systems find, diagnose and prevent these diseases, faster, more efficiently and more affordably than the current standard of care, focused on Communities, Workplaces and Homes. We are under significant pressure from our existing customers and future customers to deliver our Kidney Health Check (targeting prevention of CKD) to commercial viability within 24 months. The Kidney Health Check would deliver the equivalent of an NHS GP intervention to assess CKD risk, including serum creatinine, eGFR, NHS CKD risk engine result and other risk factors.

As a result of Innovate UK funding, we have been successful in hitting the objectives of adapting our existing technology and developed an app to digitise the results of Covid-19 rapid testing. We have secured an exclusive partnership with a major UK-based test manufacturer that gives us access to a number of world-leading tests including a CE-marked, triple antibody test, which tests for 3 antibodies, including early onset IgA antibody, which if present, indicates an active Covid-19 infection. We believe that as infection rates rise across the UK and Europe, there are large constituent groups who cannot work from home and have to enter the workplace and ensuring they do so safely is an area where rapid testing could be of massive benefit very quickly. This includes teachers, travel (e.g. airports, airlines), food preparation, manufacturing and hospitality, among others, who would benefit from a cost-effective rapid testing solution to provide results in minutes. However, without a full solution that includes the test, screening staff and a digital platform to collect test results, additional information and demographic data, it is virtually impossible to get true value from rapid testing. Further, if an employer, or workplace operator wants to understand the health of their workforce in some detail, without a digital platform and some kind of dashboard or report to collate the data from a screening, that is impossible. We believe we have two major pieces of the puzzle, namely access to world leading tests and a digital platform, via the app that was developed as part of the previous grant. We now want to focus on how rapid testing can be scaled within workforces that have to go to work and cannot work from home, to help keep workplaces Covid-free and stem the growth of the virus. We also believe that the data we will be collecting will be of value to a number of healthcare organisations, which will require sufficient interoperability in our cloud infrastructure to be able to do this efficiently. We believe we need to move quickly to prove beyond reasonable doubt that a digitally enabled rapid testing solution can be used as of now to help keep Britain working.